Try
Lakefront Biotherapeutics NV
LKFTUnited States
15 filed reports · 618 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
15 reports · Dec 2017 to Dec 2025Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 189 interim figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Annual · 20-FSEC EDGAR | 9 | 4,182 | Dec 2017 to Dec 2025 |
| Interim · 6-KSEC EDGAR | 6 | 453 | Jun 2018 to Jun 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2025 | 20-F | Dec 31, 2025 | Mar 26, 2026 | 807 | Open |
| FY2025 Q2 | 6-K | Jun 30, 2025 | Jul 24, 2025 | 12 | Open |
| FY2025 Q2 | 6-K | Jun 30, 2025 | Jul 24, 2025 | 11 | Open |
| FY2024 | 20-F | Dec 31, 2024 | Mar 27, 2025 | 349 | Open |
| FY2023 | 20-F | Dec 31, 2023 | Mar 28, 2024 | 467 | Open |
| FY2022 | 20-F | Dec 31, 2022 | Mar 23, 2023 | 517 | Open |
| FY2021 | 20-F | Dec 31, 2021 | Mar 24, 2022 | 331 | Open |
| FY2021 Q2 | 6-K | Jun 30, 2021 | Aug 5, 2021 | 142 | Open |
| FY2020 | 20-F | Dec 31, 2020 | Mar 25, 2021 | 465 | Open |
| FY2020 Q2 | 6-K | Jun 30, 2020 | Aug 6, 2020 | 90 | Open |
| FY2019 | 20-F | Dec 31, 2019 | Mar 27, 2020 | 397 | Open |
| FY2019 Q2 | 6-K | Jun 30, 2019 | Jul 25, 2019 | 87 | Open |
Financial data
618 concepts · 4,635 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial598 concepts · 4,476 facts · Dec 2005 to Dec 2025
- Cash and cash equivalents46 · Dec 2014 to Dec 2025
- Number of other equity instruments outstanding in sharebased payment arrangement32 · Dec 2014 to Dec 2025
- Equity29 · Dec 2014 to Dec 2025
- Deferred charges28 · Dec 2015 to Dec 2025
- Issued capital28 · Dec 2014 to Dec 2025
- Other reserves (IFRS)28 · Dec 2014 to Dec 2025
- Reserve of exchange differences on translation28 · Dec 2014 to Dec 2025
- Share premium (IFRS)28 · Dec 2014 to Dec 2025
- Assets (IFRS)26 · Dec 2015 to Dec 2025
- Balances with banks26 · Dec 2015 to Dec 2025
- Current assets26 · Dec 2015 to Dec 2025
- Current liabilities26 · Dec 2015 to Dec 2025
- Current R&D incentives receivables26 · Dec 2015 to Dec 2025
- Current tax liabilities (IFRS)26 · Dec 2015 to Dec 2025
- Deferred tax assets26 · Dec 2015 to Dec 2025
- Equity and liabilities26 · Dec 2015 to Dec 2025
- Intangible assets other than goodwill26 · Dec 2015 to Dec 2025
- Liabilities (IFRS)26 · Dec 2015 to Dec 2025
- Noncurrent assets (IFRS)26 · Dec 2015 to Dec 2025
- Noncurrent liabilities26 · Dec 2015 to Dec 2025
- Non-current R&D incentives receivables26 · Dec 2015 to Dec 2025
- Number of shares issued and fully paid26 · Dec 2015 to Dec 2025
- Other current assets (IFRS)26 · Dec 2015 to Dec 2025
- Other noncurrent assets (IFRS)26 · Dec 2015 to Dec 2025
Geography9 concepts · 84 facts · Dec 2015 to Dec 2025
- Revenue23 · Dec 2015 to Dec 2020
- United States of America14 · Dec 2019 to Dec 2025
- Belgium12 · Dec 2015 to Dec 2018
- Applicable tax rate11 · Dec 2015 to Dec 2025
- Other comprehensive income net of tax gains losses on remeasurements of defined benefit plans11 · Dec 2015 to Dec 2018
- Amounts due by employer to pension plans6 · Dec 2015 to Dec 2018
- New R&D incentives reported during the period4 · Dec 2016 to Dec 2017
- Switzerland, Croatia, United States and Netherlands2 · Dec 2017 to Dec 2018
- Employee contributions1 · Dec 2018
Segment8 concepts · 62 facts · Dec 2015 to Dec 2020
- Revenue18 · Dec 2015 to Jun 2020
- Profit loss from operating activities10 · Dec 2015 to Dec 2019
- Revenue and operating income (IFRS)10 · Dec 2015 to Dec 2019
- Other income (IFRS)9 · Dec 2015 to Dec 2019
- Operating Income8 · Jun 2017 to Jun 2020
- Other movements4 · Dec 2017 to Dec 2020
- Other revenue (IFRS)2 · Dec 2018 to Dec 2019
- Reimbursement income1 · Dec 2018
Product3 concepts · 13 facts · Dec 2019 to Dec 2022
- Revenue from sale of goods (IFRS)6 · Dec 2021 to Dec 2022
- Filgotinib drug license5 · Dec 2019 to Dec 2022
- Cost of sales2 · Dec 2021 to Dec 2022
Segments
159 factsFigures broken down by business line, region, product or another axis the company reports on.
Segments5 members · 62 facts
- Fee For Services23 · Dec 2015 to Dec 2020
- Research And Development20 · Dec 2015 to Dec 2019
- Fee for services segment8 · Jun 2017 to Jun 2020
- Research and development segment8 · Jun 2017 to Jun 2020
- All Other Segments3 · Dec 2018 to Dec 2019
Geographical areas8 members · 58 facts
- BE15 · Dec 2015 to Dec 2025
- Europe15 · Dec 2015 to Dec 2025
- US13 · Dec 2015 to Dec 2025
- Asia Pacific5 · Dec 2015 to Dec 2019
- FR4 · Dec 2016 to Dec 2017
- North America3 · Dec 2017 to Dec 2019
- Switzerland Croatia United States And Netherlands2 · Dec 2017 to Dec 2018
- Europe1 · Dec 2018
Statement geographicalsrt:StatementGeographicalAxis2 members · 14 facts
- BE11 · Dec 2016 to Dec 2018
- FR3 · Dec 2016 to Dec 2018
Products and services2 members · 13 facts
- Jyseleca8 · Dec 2021 to Dec 2022
- Filgotinib Drug License5 · Dec 2019 to Dec 2022
Statement geographicalus-gaap:StatementGeographicalAxis2 members · 12 facts
- BE9 · Dec 2015 to Dec 2017
- FR3 · Dec 2015 to Dec 2017
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.